A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.04.034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026. Verfasst von Harry Sokol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, 75012 Paris, France; Gut, Liver & Microbiome Research (GLIMMER)…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Gastrointestinal Tract, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Micropalaeontological Society, AstraZeneca, Merck.
Abstract (Originalsprache)
The gut ecosystem emerges as a key determinant of immune checkpoint inhibitor (ICI) efficacy. Rather than individual "beneficial" bacteria, a broader framework of gut health better explains inter-individual variability in ICI response: a non-inflamed gastrointestinal tract with preserved epithelial barrier and functionally eubiotic microbiome promotes responsiveness, whereas gut inflammation and barrier disruption predict poor outcomes. By integrating human and mechanistic mouse data, we propose shifting the research focus toward clinically actionable gut-health axes to optimize cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, 75012 Paris, France; Gut, Liver & Microbiome Research (GLIMMER) FHU, 75012 Paris, France; Université Paris-Saclay, INRAE, AgroParisTe…
- Axe Cancer, Centre de recherche Du Centre Hospitalier de L'Université de Montréal (CRCHUM), Montréal, QC, Canada; Hemato-Oncology Division, Centre Hospitalier de L'Université de Montréal (CHUM), Montréal, QC, Canada.
Förderung
- Micropalaeontological Society
- AstraZeneca
- Merck
Zitieren
APA
Sokol, H., Elkrief, A., & Routy, B. (2026). A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.04.034
Vancouver
Sokol H, Elkrief A, Routy B. A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.04.034
BibTeX
@article{Sokol2026,
author = {Sokol, Harry and Elkrief, Arielle and Routy, Bertrand},
title = {A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.04.034}
}
EUVIMED